ReST is Redefining Precision Neuropsychiatry
Our innovative treatment approach will transform treatment and access for patients
Identify Unmet Medical Need
We focus on diseases with limited or no effective therapies. They are screened to ensure the maximum clinical impact for patients by addressing specific symptoms and significantly improving patients’ outcomes and quality of life.
Target Engagement
ReST’s molecular platform is built on a unique mechanism of action targeting specific NMDA receptors subunits and specific disease pathophysiology for superior efficacy and tolerability.
Robust Preclinical Models
Disease specific preclinical models are developed to validate scientific rationale and maximize translatability of the results.
Our Team
Leadership Team Combines Expertise in Drug Development, Patient Advocacy and Business Growth
Anthony R. Franco, JD
General Manager
Gilles Rubinstenn, PhD, MBA
Chief Innovation Officer
Chairman & Founder
Reina Benabou, MD, PhD
Chief Medical Officer
Addressing the PTSD Epidemic
Our Lead Program, RST-101, is Targeting the Early Treatment of Post Traumatic Stress Disorder.
Despite recent advancements millions are left without satisfactory solutions
Global Prevalence
300M
Military Veterans
23%
Female Gender disparity
2:1
Likelihood of addiction
10X
Attempted Suicide Risk
20%
Partners and Collaborators
ReST Therapeutics is Supported by a Global Network of Academic and Scientific Collaborators
ReST Therapeutics
Global Office Locations